ETF Holdings Breakdown of ADPT

Stock NameAdaptive Biotechnologies Corp
TickerADPT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS00650F1093
LEI549300ZTF7OT1FW66Q96

News associated with ADPT

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives $10.57 Average Target Price from Brokerages
Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) have received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target […] - 2025-06-27 05:10:57
Adaptive Biotechnologies Reaches Analyst Target Price
In recent trading, shares of Adaptive Biotechnologies Corp (Symbol: ADPT) have crossed above the average analyst 12-month target price of $11.62, changing hands for $11.98/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: dow - 2025-06-26 11:37:35
Adaptive Biotechnologies (NASDAQ:ADPT) Coverage Initiated at Craig Hallum
Equities research analysts at Craig Hallum assumed coverage on shares of Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) in a research note issued to investors on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $15.00 price target on the stock. Craig Hallum’s price target would suggest a potential upside of 43.27% from […] - 2025-06-20 05:15:14
Brighton Jones LLC Has $166,000 Stock Position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT)
Brighton Jones LLC decreased its position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Free Report) by 8.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,318 shares of the company’s stock after selling 1,971 shares during the period. Brighton Jones […] - 2025-06-19 08:35:04
Rhumbline Advisers Acquires 7,322 Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT)
Rhumbline Advisers raised its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Free Report) by 4.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 188,524 shares of the company’s stock after buying an additional 7,322 shares during the quarter. Rhumbline Advisers’ holdings in Adaptive […] - 2025-06-19 07:42:43
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) during the fourth quarter, Holdings Channel reports. The fund bought 118,593 shares of the company’s stock, valued at approximately $711,000. A number of other institutional investors also recently bought […] - 2025-06-11 07:38:55
Analysts Set Adaptive Biotechnologies Co. (NASDAQ:ADPT) Target Price at $9.83
Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Free Report) have received a consensus rating of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year […] - 2025-06-02 05:50:50
Quantinno Capital Management LP Takes Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Quantinno Capital Management LP acquired a new stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 16,688 shares of the company’s stock, valued at approximately $100,000. A number of other […] - 2025-05-29 07:59:02
Deutsche Bank AG Grows Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Deutsche Bank AG boosted its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 397.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 630,577 shares of the company’s stock after buying an additional 503,842 shares during the period. Deutsche Bank AG owned approximately […] - 2025-05-20 08:14:56
Adaptive Biotechnologies (NASDAQ:ADPT) Sees Strong Trading Volume Following Analyst Upgrade
Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Free Report) saw unusually-strong trading volume on Monday after Morgan Stanley raised their price target on the stock from $7.00 to $9.00. Morgan Stanley currently has an equal weight rating on the stock. Approximately 1,380,969 shares traded hands during mid-day trading, a decline of 11% from the […] - 2025-05-07 05:21:01
Adaptive Biotechnologies Reaches Analyst Target Price
In recent trading, shares of Adaptive Biotechnologies Corp (Symbol: ADPT) have crossed above the average analyst 12-month target price of $9.86, changing hands for $10.03/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down - 2025-05-06 11:20:53
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Expected to Rise, Morgan Stanley Analyst Says
Adaptive Biotechnologies (NASDAQ:ADPT – Free Report) had its price target lifted by Morgan Stanley from $7.00 to $9.00 in a research report released on Monday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock. Other analysts have also recently issued research reports about the stock. Scotiabank raised their price objective on […] - 2025-05-06 05:55:06
Guggenheim Capital LLC Cuts Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Guggenheim Capital LLC trimmed its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 19.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,845 shares of the company’s stock after selling 10,093 shares during the quarter. Guggenheim Capital LLC’s […] - 2025-04-29 08:30:55
Prudential Financial Inc. Boosts Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Prudential Financial Inc. grew its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 3,290.8% during the 4th quarter, HoldingsChannel reports. The fund owned 481,965 shares of the company’s stock after purchasing an additional 467,751 shares during the period. Prudential Financial Inc.’s holdings in Adaptive Biotechnologies were worth $2,889,000 at the end of the […] - 2025-04-03 08:16:55
Intech Investment Management LLC Purchases 11,865 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Intech Investment Management LLC increased its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 34.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 46,158 shares of the company’s stock after buying an additional 11,865 shares during the period. Intech Investment Management LLC’s holdings in Adaptive Biotechnologies were worth $277,000 as of its […] - 2025-03-27 08:22:57
Adaptive Biotechnologies (NASDAQ:ADPT) Upgraded at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of Adaptive Biotechnologies (NASDAQ:ADPT – Free Report) from a neutral rating to a buy rating in a research report released on Friday, Marketbeat.com reports. The Goldman Sachs Group currently has $9.00 price objective on the stock, up from their previous price objective of $8.00. ADPT has been the topic […] - 2025-03-24 06:28:56
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Down 6.1% on Insider Selling
Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Free Report)’s stock price fell 6.1% on Thursday after an insider sold shares in the company. The company traded as low as $7.46 and last traded at $7.15. 41,184 shares changed hands during trading, a decline of 98% from the average session volume of 1,692,515 shares. The stock had […] - 2025-03-14 06:23:07
Caprock Group LLC Sells 2,500 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Caprock Group LLC lessened its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 19.4% during the 4th quarter, Holdings Channel reports. The firm owned 10,415 shares of the company’s stock after selling 2,500 shares during the quarter. Caprock Group LLC’s holdings in Adaptive Biotechnologies were worth $62,000 at the end of the most […] - 2025-02-08 08:49:17
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Purchased by China Universal Asset Management Co. Ltd.
China Universal Asset Management Co. Ltd. increased its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 10.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 31,292 shares of the company’s stock after buying an additional 2,928 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Adaptive Biotechnologies […] - 2025-02-04 08:53:02

ADPT institutional holdings

The following institutional investment holdings of ADPT have been identified

Date ETF ISIN/Name Num Shares Book value
2025-06-26 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 190,913USD 2,321,502
2025-06-26 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 75,812USD 921,874
2025-06-26 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 75,812USD 921,874
2025-06-26 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 61,736USD 750,710
2025-06-26 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 11,047USD 134,332
Total =415,320 USD 5,050,292
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.